COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
摘要:
The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.
[EN] NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS<br/>[FR] NOUVEAUX COMPOSÉS UTILES COMME LIGANDS DE RÉCEPTEUR DE CHÉMOKINE CC
申请人:FOREST LAB HOLDINGS LTD
公开号:WO2010077915A1
公开(公告)日:2010-07-08
The present invention relates to novel morpholine, oxazapane and piperidine derivatives that act as ligands for CC chemokine receptors, such as CCRl. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.
NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS
申请人:KHAMRAI Uttam
公开号:US20100168080A1
公开(公告)日:2010-07-01
The present invention relates to novel morpholine, oxazapane and piperidine derivatives that act as ligands for CC chemokine receptors, such as CCR1. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.
COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
申请人:[en]NMD PHARMA A/S
公开号:WO2024121130A1
公开(公告)日:2024-06-13
The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.